Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Levothyroxine sodium
Test Euthyrox · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1:Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox® | EXPERIMENTAL | Participants will receive single oral dose of Test Euthyrox® on in treatment period 1, followed by single oral dose of Reference Euthyrox® in treatment period 2, followed by single oral dose of Test Euthyrox® in treatment period 3, followed by single oral dose of Reference Euthyrox in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period. |
| Sequence 2:Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox® | EXPERIMENTAL | Participants will receive single oral dose of Reference Euthyrox® in treatment period 1, followed by single oral dose of Test Euthyrox® in treatment period 2, followed by single oral dose of Reference Euthyrox® in treatment period 3, followed by single oral dose of Test Euthyrox® in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period. |
| Name | Type | Description |
|---|---|---|
| Test Euthyrox® | DRUG | Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4. |
| Reference Euthyrox® | DRUG | Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4. |
Inclusion Criteria: * Participants have a body weight within 45 to 75 kilogram (kg) for females and 55 to 85 kg for males and Body mass index (BMI) within the range 19.0 to 26.0 kilograms per meter square (kg/m\^2) * Non-smoker for at least 3 months * Contraceptive use by males or females will be c...
Test Euthyrox is an investigational small molecule developed by Merck KGaA. It has been studied in a Phase 1 clinical trial conducted in China involving 56 healthy adult volunteers. The specific therapeutic indication for Test Euthyrox has not been publicly disclosed.
Test Euthyrox is developed by Merck KGaA, which trades under the ticker MKGAF. The company sponsored the clinical evaluation of the drug candidate.
Test Euthyrox is in Phase 1 clinical development. It is an investigational drug candidate and is not approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.
Test Euthyrox has been evaluated in one completed Phase 1 trial, NCT05174000. The study was titled "BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)" and enrolled 56 healthy adult volunteers in China. It was a randomized, controlled trial.
Yes, Test Euthyrox and Test Euthyrox® refer to the same drug candidate. Test Euthyrox® is the registered trademark form of the name used by developer Merck KGaA. Both names identify the same investigational small molecule in Phase 1 development.